Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from ImmuPharma ( (GB:IMM) ).
ImmuPharma has reported progress on its P140 autoimmune technology platform, receiving a supportive first Combined Search and Examination Report for its UK patent application filed in September 2025. The company plans to follow this with a Patent Cooperation Treaty filing to secure protection in key commercial territories, underlining the strategic importance of P140 to its pipeline.
A new study designed to stress test the associated diagnostic and strengthen statistical robustness produced positive results that back the patent case, and a scientific manuscript detailing P140’s mechanism of action is being prepared for submission to a peer‑reviewed journal. Management continues active partnering talks, including meetings at the Bio‑Europe Spring conference, and remains focused on securing a value‑enhancing licensing deal around P140 in 2026, a move that could materially influence ImmuPharma’s future revenues and industry positioning.
The most recent analyst rating on (GB:IMM) stock is a Sell with a £6.00 price target. To see the full list of analyst forecasts on ImmuPharma stock, see the GB:IMM Stock Forecast page.
Spark’s Take on IMM Stock
According to Spark, TipRanks’ AI Analyst, IMM is a Neutral.
The score is weighed down primarily by very weak financial performance (near-zero revenue, persistent losses, ongoing cash burn, and negative equity). Technicals are mixed but modestly supportive versus the 200-day average, while valuation remains challenged due to losses and the absence of dividend yield.
To see Spark’s full report on IMM stock, click here.
More about ImmuPharma
ImmuPharma PLC is a UK‑listed specialty biopharmaceutical company focused on discovering and developing peptide‑based therapeutics. Its portfolio targets autoimmune diseases and anti‑infective indications, positioning the group within the high‑value niche of precision therapies for immune‑mediated disorders.
Average Trading Volume: 3,581,996
Technical Sentiment Signal: Sell
Current Market Cap: £22.85M
For detailed information about IMM stock, go to TipRanks’ Stock Analysis page.